Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Triple Negative Breast Neoplasms × Base Sequence × Clear all

Status

Withdrawn 1 Recruiting 1

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 2 Breast Neoplasms 2 Triple Negative Breast Neoplasms 1 Recurrence 1 Radiation Injuries 1 Oropharyngeal Neoplasms 1 Neoplasms 1 Head and Neck Neoplasms 1 Cholangiocarcinoma 1 Cervical Cancer Susceptible Population Classification 1 Biliary Tract Neoplasms 1

Interventions

pembrolizumab 50 Carboplatin 28 Paclitaxel 19 Cyclophosphamide 16 sacituzumab govitecan 15 Capecitabine 13 130-nm albumin-bound paclitaxel 13 Specimen Handling 11 Magnetic Resonance Spectroscopy 9 Drug Therapy 9 Docetaxel 9 Bevacizumab 9 toripalimab 8 olaparib 7 durvalumab 7 Doxorubicin 7 Biopsy 7 Epirubicin 6 Albumin-Bound Paclitaxel 6 camrelizumab 5 Taxes 5 Nivolumab 5 atezolizumab 4 Injections 4 Immune Checkpoint Inhibitors 4 tucatinib 3 tislelizumab 3 liposomal doxorubicin 3 fludarabine 3 eribulin 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT05916755 2023-06-23

PORTRAIT

Vall d'Hebron Institute of Oncology

Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡